Britannia Life Sciences Inc. BLAB
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -37.31% | -63.69% | 198.29% | 205.41% | 228.35% |
| Total Depreciation and Amortization | -21.87% | -21.02% | -62.06% | -65.15% | -74.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 73.32% | 84.00% | -249.94% | -275.13% | -305.37% |
| Change in Net Operating Assets | -3,683.22% | -411.53% | -195.38% | -122.76% | -106.05% |
| Cash from Operations | 57.86% | 2.99% | -554.30% | -548.08% | -358.19% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -38.49% | -153.08% | 1,181.54% | 1,419.56% | 3,384.79% |
| Cash from Investing | -38.49% | -153.08% | 1,161.63% | 463.46% | 952.73% |
| Total Debt Issued | -- | -- | 27.98% | 13.85% | 6,124.44% |
| Total Debt Repaid | 92.85% | 92.32% | -66.94% | -0.28% | 28.94% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 88.40% | 29.97% | -159.18% |
| Cash from Financing | 108.57% | 92.92% | 79.43% | 33.36% | 66.15% |
| Foreign Exchange rate Adjustments | -9.94% | -99.06% | -117.60% | -111.61% | 226.57% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.96% | -224.03% | 8.52% | 57.75% | 399.88% |